| Outcome Measures: |
Primary: area under curve (AUC), To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19|maximum plasma concentration (Cmax), To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19|terminal elimination half-life (t1/2), To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19|time to reach maximum plasma concentration (Tmax), To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19 | Secondary: measure the effects on Insulin and C-peptide Levels, To assess the effects of single oral dose of DS-1150b on insulin and C-peptide levels in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19|number of patients experiencing adverse events, To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus., 24 days, Day -5 to Day 19|measure the effects on glucagon Levels, To assess the effects of single oral dose of DS-1150b on glucagon levels in subjects with Type 2 Diabetes Mellitus., 24 days, Day -5 to Day 19|number of patients experiencing laboratory adverse events, To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus., 24 days, Day -5 to Day 19
|
